Drug Profile
DCR PH1
Alternative Names: DCR-PH1Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Dicerna Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Primary hyperoxaluria
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 10 Aug 2017 Dicerna Pharmaceuticals terminates a phase I trial in Primary hyperoxaluria (In adolescents, In adults) in United Kingdom, Netherlands and Germany (IV)
- 10 Aug 2017 Dicerna Pharmaceuticals terminates a phase I trial in Primary hyperoxaluria (In volunteers) (IV)